MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $221.82 million. The enterprise value is $68.67 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 63.56 million shares outstanding. The number of shares has increased by 0.85% in one year.
| Current Share Class | 63.56M |
| Shares Outstanding | 63.56M |
| Shares Change (YoY) | +0.85% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 2.58% |
| Owned by Institutions (%) | 53.54% |
| Float | 55.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| Forward PS | 3.48 |
| PB Ratio | 3.98 |
| P/TBV Ratio | 3.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.10, with a Debt / Equity ratio of 0.66.
| Current Ratio | 5.10 |
| Quick Ratio | 4.71 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.56 |
Financial Efficiency
Return on equity (ROE) is -86.95% and return on invested capital (ROIC) is -37.03%.
| Return on Equity (ROE) | -86.95% |
| Return on Assets (ROA) | -17.56% |
| Return on Invested Capital (ROIC) | -37.03% |
| Return on Capital Employed (ROCE) | -34.08% |
| Weighted Average Cost of Capital (WACC) | 11.42% |
| Revenue Per Employee | $510,239 |
| Profits Per Employee | -$254,676 |
| Employee Count | 293 |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -672,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +170.54% in the last 52 weeks. The beta is 1.10, so MacroGenics's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +170.54% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 1.83 |
| Relative Strength Index (RSI) | 65.85 |
| Average Volume (20 Days) | 881,639 |
Short Selling Information
The latest short interest is 3.78 million, so 5.95% of the outstanding shares have been sold short.
| Short Interest | 3.78M |
| Short Previous Month | 3.98M |
| Short % of Shares Out | 5.95% |
| Short % of Float | 6.80% |
| Short Ratio (days to cover) | 2.54 |
Income Statement
In the last 12 months, MacroGenics had revenue of $149.50 million and -$74.62 million in losses. Loss per share was -$1.18.
| Revenue | 149.50M |
| Gross Profit | -33.68M |
| Operating Income | -72.84M |
| Pretax Income | -75.29M |
| Net Income | -74.62M |
| EBITDA | -65.67M |
| EBIT | -72.84M |
| Loss Per Share | -$1.18 |
Full Income StatementBalance Sheet
The company has $189.91 million in cash and $36.76 million in debt, with a net cash position of $153.15 million or $2.41 per share.
| Cash & Cash Equivalents | 189.91M |
| Total Debt | 36.76M |
| Net Cash | 153.15M |
| Net Cash Per Share | $2.41 |
| Equity (Book Value) | 55.59M |
| Book Value Per Share | 0.88 |
| Working Capital | 176.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.04 million and capital expenditures -$1.91 million, giving a free cash flow of -$82.95 million.
| Operating Cash Flow | -81.04M |
| Capital Expenditures | -1.91M |
| Depreciation & Amortization | 7.17M |
| Net Borrowing | n/a |
| Free Cash Flow | -82.95M |
| FCF Per Share | -$1.31 |
Full Cash Flow StatementMargins
Gross margin is -22.53%, with operating and profit margins of -48.72% and -49.91%.
| Gross Margin | -22.53% |
| Operating Margin | -48.72% |
| Pretax Margin | -50.36% |
| Profit Margin | -49.91% |
| EBITDA Margin | -43.93% |
| EBIT Margin | -48.72% |
| FCF Margin | n/a |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.85% |
| Shareholder Yield | -0.85% |
| Earnings Yield | -33.64% |
| FCF Yield | -37.40% |
Analyst Forecast
The average price target for MacroGenics is $4.60, which is 31.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.60 |
| Price Target Difference | 31.81% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | -1.95% |
| EPS Growth Forecast (5Y) | 0.54% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -5.97 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.97 |
| Piotroski F-Score | 3 |
